410 related articles for article (PubMed ID: 26324807)
1. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
[TBL] [Abstract][Full Text] [Related]
2. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
[TBL] [Abstract][Full Text] [Related]
4. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
5. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
6. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
7. The objective evaluation of obstructive pulmonary diseases with spirometry.
Ozkaya S; Dirican A; Tuna T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2009-15. PubMed ID: 27616884
[TBL] [Abstract][Full Text] [Related]
8. Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis.
Wei J; Pang CS; Han J; Yan H
Adv Ther; 2019 Dec; 36(12):3356-3367. PubMed ID: 31598901
[TBL] [Abstract][Full Text] [Related]
9. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Sathananthan K; Fortescue R
Cochrane Database Syst Rev; 2019 May; 5(5):CD001287. PubMed ID: 31107966
[TBL] [Abstract][Full Text] [Related]
10. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L; Xiong Y; Du L
Biomed Res Int; 2022; 2022():9133777. PubMed ID: 35795313
[TBL] [Abstract][Full Text] [Related]
13. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
14. Phenotype/endotype-driven therapy in COPD: potential economic implications.
Antoniu SA
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):421-3. PubMed ID: 23977968
[No Abstract] [Full Text] [Related]
15. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
16. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
[TBL] [Abstract][Full Text] [Related]
17. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Teo E; House H; Lockhart K; Purchuri SN; Pushparajah J; Cripps AW; van Driel ML
Cochrane Database Syst Rev; 2014 Sep; (9):CD010010. PubMed ID: 25201571
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
20. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Stey C; Steurer J; Bachmann S; Medici TC; Tramèr MR
Eur Respir J; 2000 Aug; 16(2):253-62. PubMed ID: 10968500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
